Inflammatory mechanisms in Alzheimer's disease: implications for therapy.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  American Journal of Psychiatry

• Publication date

  1994-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1176/AJP.151.8.1105PMID 7518651
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gold salts in the treatment of rheumatoid arthritis. A double-blind study.

  2020cited by this paper
• Inverse association of anti‐inflammatory treatments and Alzheimer's disease

  1994cited by this paper
• Clinical trial of indomethacin in Alzheimer's disease

  1993cited by this paper
• Complement activation by beta-amyloid in Alzheimer disease.

  1992cited by this paper
• The Stress Response and the Regulation of Inflammatory Disease

  1992cited by this paper
• The role of the acute-phase protein alpha 1-antichymotrypsin in brain dysfunction and injury.

  1992cited by this paper
• Complement inhibitor C4-binding protein in amyloid deposits containing serum amyloid P in Alzheimer's disease.

  1992cited by this paper
• Ocular Safety of Hydroxychloroquine Sulfate (Plaquenil)

  1992cited by this paper
• Serological alpha 1-antichymotrypsin in Down's syndrome and Alzheimer's disease.

  1992cited by this paper
• Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials.

  1992cited by this paper
• Cytokines and inflammatory proteins in Alzheimer's disease.

  1992cited by this paper
• Chloroquine inhibits intracellular degradation but not secretion of Alzheimer beta/A4 amyloid precursor protein.

  1992cited by this paper
• Processing of the amyloid protein precursor to potentially amyloidogenic derivatives.

  1992cited by this paper
• Distribution pattern and functional state of complement proteins and alpha 1-antichymotrypsin in cerebral beta/A4 deposits in Alzheimer's disease.

  1992cited by this paper
• Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease.

  1992cited by this paper
• Complements, microglial cells and amyloid fibril formation.

  1992cited by this paper
• The disordered neuronal cytoskeleton in Alzheimer's disease.

  1992cited by this paper
• Complement proteins and complement inhibitors in Alzheimer's disease.

  1992cited by this paper
• A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

  1992cited by this paper
• Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor.

  1992cited by this paper
• ANTI‐INFLAMMATORY AND IMMUNOSUPPRESSIVE EFFECTS OF RECOMBINANT SOLUBLE COMPLEMENT RECEPTORS

  1991cited by this paper
• Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert.

  1991cited by this paper
• Developmental expression of alpha 1-antichymotrypsin in brain may be related to astrogliosis.

  1991cited by this paper
• Leakage and neuronal uptake of serum protein in aged and Alzheimer brains. A postmortem phenomenon with antemortem etiology.

  1991cited by this paper
• The acute phase response: from Hippocrates to cytokine biology.

  1991cited by this paper
• Cytokines as modulators of the hypothalamus-pituitary-adrenal axis.

  1991cited by this paper
• The predominant form of the amyloid beta-protein precursor in human brain is protease nexin 2.

  1991cited by this paper
• Anatomic, metabolic, neuropsychological, and molecular genetic studies of three pairs of identical twins discordant for dementia of the Alzheimer's type.

  1991cited by this paper
• Elevated circulating tumor necrosis factor levels in Alzheimer's disease.

  1991cited by this paper
• Processing of beta-amyloid precursor protein in microglia and astrocytes favors an internal localization over constitutive secretion

  1991cited by this paper
• Serum Amyloid P in Alzheimer's Disease

  1991cited by this paper
• Toxic and Metabolic Encephalopathies in Long-Term Care Patients

  1991cited by this paper
• Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices.

  1991cited by this paper
• Alzheimer beta/A4 amyloid precursor protein in human brain: aging-associated increases in holoprotein and in a proteolytic fragment.

  1991cited by this paper
• Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain?

  1991cited by this paper
• Cytokines in Alzheimer's disease.

  1991cited by this paper
• Enzyme specificity of proteinase inhibitor region in amyloid precursor protein of Alzheimer's disease: different properties compared with protease nexin I.

  1990cited by this paper
• Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimer's disease.

  1990cited by this paper
• Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain.

  1990cited by this paper
• Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord

  1990cited by this paper
• Adrenal secretion of cortisol in patients with rheumatoid arthritis.

  1990cited by this paper
• Alpha 1-antichymotrypsin is associated solely with amyloid deposits containing the beta-protein. Amyloid and cell localization of alpha 1-antichymotrypsin.

  1990cited by this paper
• Anti-inflammatory drugs and Alzheimer disease.

  1990cited by this paper
• Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease.

  1990cited by this paper
• The Alzheimer's amyloid precursor protein is produced by type I astrocytes in primary cultures of rat neuroglia

  1990cited by this paper
• Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia.

  1990cited by this paper
• Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta.

  1990cited by this paper
• Cleavage of amyloid beta peptide during constitutive processing of its precursor.

  1990cited by this paper
• Inhibition of interleukin-1 release by IX 207-887

  1990cited by this paper
• Plasma and cerebrospinal fluid concentrations of indomethacin in humans

  1990cited by this paper
• Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease.

  1989cited by this paper
• Activation of the classical complement pathway in brain tissue of Alzheimer patients.

  1989cited by this paper
• Immune System Response in Alzheimer's Disease

  1989cited by this paper
• Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

  1989cited by this paper
• Astrocytes in Alzheimer's disease gray matter express alpha 1-antichymotrypsin mRNA.

  1989cited by this paper
• Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain

  1989cited by this paper
• Monozygotic twins discordant for Alzheimer's disease

  1989cited by this paper
• Interleukin‐6 is the major regulator of acute phase protein synthesis in adult human hepatocytes

  1989cited by this paper
• Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs in the cerebrospinal fluid.

  1989cited by this paper
• Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells.

  1989cited by this paper
• On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases

  1989cited by this paper
• Dapsone in temporal arteritis and polymyalgia rheumatica.

  1988cited by this paper
• The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes.

  1988cited by this paper
• Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease.

  1988cited by this paper
• Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease.

  1988cited by this paper
• Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue.

  1988cited by this paper
• Complement activation in amyloid plaques in Alzheimer’s dementia

  1988cited by this paper
• The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

  1987cited by this paper
• Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro.

  1987cited by this paper
• Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR.

  1987cited by this paper
• A hypothesis concerning the role of endogenous colchicine-like factors in the etiology of Alzheimer's disease.

  1987cited by this paper
• Effect of sulphasalazine on the radiological progression of rheumatoid arthritis.

  1987cited by this paper
• Cortisol and Alzheimer's disease, I: Basal studies.

  1986cited by this paper
• Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever.

  1986cited by this paper
• Interleukin 1 of the central nervous system is produced by ameboid microglia

  1986cited by this paper
• Efficacy of oral physostigmine in primary degenerative dementia

  1985cited by this paper
• Oral physostigmine treatment of patients with Alzheimer's disease.

  1985cited by this paper
• A mechanism for glucocorticoid toxicity in the hippocampus: increased neuronal vulnerability to metabolic insults

  1985cited by this paper
• Amyloid plaque core protein in Alzheimer disease and Down syndrome.

  1985cited by this paper
• Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging

  1985cited by this paper
• Hydroxychloroquine sulfate in rheumatoid arthritis: long-term response rate and predictive parameters.

  1983cited by this paper
• Immunosuppressive potential of antimalarials.

  1983cited by this paper
• Cognitive dysfunction associated with naproxen and ibuprofen in the elderly.

  1982cited by this paper
• D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis.

  1982cited by this paper
• Immunoglobulins and complement factors in senile plaques

  1982cited by this paper
• Role of microtubuli in the lysosomal degradation of endogenous and exogenous protein in isolated rat hepatocytes.

  1981cited by this paper
• Inhibition of lysosomal phospholipase A and phospholipase C by chloroquine and 4,4'-bis(diethylaminoethoxy) alpha, beta-diethyldiphenylethane.

  1980cited by this paper
• Hippocampal aging and adrenocorticoids: quantitative correlations.

  1978cited by this paper
• Colchicine effects on lysosomal enzyme induction and intracellular degradation in the cultivated macrophage

  1975cited by this paper
• Commentary. Lysosomotropic agents.

  1974cited by this paper
• Colchicine.

  1974cited by this paper
• The effects of some anti-inflammatory drugs on the acute-phase proteins in rheumatoid arthritis.

  1973cited by this paper
• IMMUNOLOGIC STUDIES OF THE MAJOR NONIMMUNOGLOBULIN PROTEIN OF AMYLOID

  1973cited by this paper
• The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils.

  1972cited by this paper
• Adrenal glucocorticoids after twenty years. A review of their clinically relevant consequences.

  1970cited by this paper
• SUPPRESSION OF IN VITRO LYMPHOCYTE RESPONSES BY CHLOROQUINE.

  1965cited by this paper
• Hydroxychloroquine sulfate ("plaguenil") in treatment of rheumatoid arthritis.

  1962cited by this paper
• Chloroquine Diphosphate in Rheumatoid Arthritis *

  1961cited by this paper
• Plaquenil in the treatment of lupus erythematosus.

  1956cited by this paper
• Distribution of Radioactive Colchicine in Some Organs of Normal and Tumor-bearing Mice.∗

  1951cited by this paper

• Can IVIG Intervene in AD? Insights from Animal Experiments and Clinical Trials—A Systematic Review and Synthesis Without Meta-Analysis

  2026cites this paper
• Pioglitazone attenuates complement-mediated microglial synaptic engulfment in an Alzheimer's disease model.

  2025cites this paper
• Modulating Neuroinflammation as a Prospective Therapeutic Target in Alzheimer’s Disease

  2025cites this paper
• Tratamiento de la enfermedad de Alzheimer

  2025cites this paper
• Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies

  2024cites this paper
• Anti-Inflammatory Effects of GPR55 Agonists and Antagonists in LPS-Treated BV2 Microglial Cells

  2024cites this paper
• Is Drp1 a link between mitochondrial dysfunction and inflammation in Alzheimer’s disease?

  2023cites this paper
• Neuroinflammation: A Common Pathway in Alzheimer’s Disease and Epilepsy

  2023cites this paper
• Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer’s Disease

  2023cites this paper
• Revisiting the neuroinflammation hypothesis in Alzheimer’s disease: a focus on the druggability of current targets

  2023cites this paper
• Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential

  2022cites this paper
• The emerging role of furin in neurodegenerative and neuropsychiatric diseases

  2022cites this paper
• Kurt Jellinger 90: his contribution to neuroimmunology

  2021cites this paper
• Normal aging, motor neurone disease, and Alzheimer’s disease are characterized by cortical changes in inflammatory cytokines

  2021cites this paper
• Implication of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase and Its Inhibitors in Alzheimer’s Disease Murine Models

  2021cites this paper
• Nilotinib Improves Bioenergetic Profiling in Brain Astroglia in the 3xTg Mouse Model of Alzheimer’s Disease

  2021cites this paper
• BRD4 contributes to LPS-induced macrophage senescence and promotes progression of atherosclerosis-associated lipid uptake

  2020cites this paper
• Sigma ligands as potent inhibitors of Aβ and AβOs in neurons and promising therapeutic agents of Alzheimer's disease.

  2020cites this paper
• Cognitive improvements and reduction in amyloid plaque deposition by saikosaponin D treatment in a murine model of Alzheimer's disease

  2020cites this paper
• The Role of the Gut Brain Axis and Microbiome in Colorectal Cancer, Alzheimer's Disease, and Crohn's Disease

  2019cites this paper
• Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old

  2019cites this paper
• Neuroimmune Mechanisms In The Pathogenesis Of Alzheimer’s Disease

  2019cites this paper
• The Black Book of Psychotropic Dosing and Monitoring.

  2018cites this paper
• Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease.

  2018cites this paper
• Potential Role of the Gut Microbiome in ALS: A Systematic Review

  2018cites this paper
• Cerebrospinal fluid from Alzheimer patients affects cell‐mediated nerve growth factor production and cell survival in vitro

  2018cites this paper
• Depression & cognition in the elderly : neuroimaging perspective

  2017cites this paper
• The therapeutic model of Group Analytic Psychotherapy in Brain's Plasticity modification and expression, in patients with Cognitive and Psychiatric Disorders: A Hypothesis of Neuron-Immune-Analysis and Neuron-Immune-modulation.

  2017cites this paper
• Seeking a New Paradigm for Alzheimer's Disease: Considering the Roles of Inflammation, Blood-Brain Barrier Dysfunction, and Prion Disease

  2017cites this paper
• Inflammation Friend or Foe

  2017cites this paper
• Anti‐inflammatory and protective effects of MT‐031, a novel multitarget MAO‐A and AChE/BuChE inhibitor in scopolamine mouse model and inflammatory cells

  2017influential citation
• High C‐Reactive Protein Predicts Delirium Incidence, Duration, and Feature Severity After Major Noncardiac Surgery

  2017cites this paper
• Down regulation of pro‐inflammatory pathways by tanshinone IIA and cryptotanshinone in a non‐genetic mouse model of Alzheimer's disease

  2017cites this paper
• Complement in the pathogenesis of Alzheimer’s disease

  2017cites this paper
• Epidemiology and risk factors for dementia

  2016cites this paper
• Differential burden of rare protein truncating variants in Alzheimer’s disease patients compared to centenarians

  2016cites this paper
• Differential burden of rare protein truncating variants in Alzheimer's disease patients compared to centenarians.

  2016cites this paper
• Neuronal Gene Targets of NF-κB and Their Dysregulation in Alzheimer's Disease

  2016cites this paper
• Human gut microbiota: the links with dementia development

  2016cites this paper
• KCa3.1 constitutes a pharmacological target for astrogliosis associated with Alzheimer's disease.

  2016cites this paper
• Molecular imaging of neuroinflammation in Alzheimer’s disease

  2015cites this paper
• Cognitive Enhancers and Treatments for Alzheimer's Disease

  2015cites this paper
• Caruifolin D from artemisia absinthium L. inhibits neuroinflammation via reactive oxygen species-dependent c-jun N-terminal kinase and protein kinase c/NF-κB signaling pathways.

  2015cites this paper
• The role of complement in neurological and neuropsychiatric diseases

  2015cites this paper
• Soluble epoxide hydrolase activity regulates inflammatory responses and seizure generation in two mouse models of temporal lobe epilepsy.

  2015cites this paper
• A New Role for Beta-Amyloid in Alzheimer's Disease: Initiation of Thrombotic and Inflammatory Processes Via Coagulation Factor XII and Fibrinogen

  2015cites this paper
• Shared Neuropathological Characteristics of Obesity, Type 2 Diabetes and Alzheimer’s Disease: Impacts on Cognitive Decline

  2015cites this paper
• Ibuprofen in Prevention of Neurodegenerative Diseases

  2015cites this paper
• S100B Inhibitor Pentamidine Attenuates Reactive Gliosis and Reduces Neuronal Loss in a Mouse Model of Alzheimer's Disease

  2015cites this paper
• Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis

  2015cites this paper
• Multi-faced neuroprotective effects of geniposide depending on the RAGE-mediated signaling in an Alzheimer mouse model.

  2015cites this paper
• Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice: Correlations With Plaques, Tangles, and Oligomeric Species

  2015cites this paper
• Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications

  2014cites this paper
• Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging

  2014cites this paper
• Geniposide attenuates oligomeric Aβ(1-42)-induced inflammatory response by targeting RAGE-dependent signaling in BV2 cells.

  2014cites this paper
• Cholinergic system dysfunction and neurodegenerative diseases: cause or effect?

  2014cites this paper
• Creation and Characterization of a Sensitized, Inhibitable Stress-Activated Protein Kinase

  2014cites this paper
• Alzheimer’s Disease and Animal Models in Retrospect

  2014cites this paper
• The adsorption behaviour of buffered aspirin monitored by Raman and surface-enhanced Raman spectroscopy.

  2014cites this paper
• D-Ala2GIP Facilitated Synaptic Plasticity and Reduces Plaque Load in Aged Wild Type Mice and in an Alzheimer's Disease Mouse Model

  2013cites this paper
• Elusive Alzheimer's disease: can immune signatures help our understanding of this challenging disease? Part 2: new immune paradigm.

  2013cites this paper
• Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model

  2013cites this paper
• The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease.

  2013cites this paper
• Role of Scavenger Receptors in Glia-Mediated Neuroinflammatory Response Associated with Alzheimer's Disease

  2013cites this paper
• Regulation of excitotoxicity in thiamine deficiency: role of glutamate transporters.

  2013cites this paper
• Impairment of the ABCA1 and SR-BI-mediated cholesterol efflux pathways and HDL anti-inflammatory activity in Alzheimer's disease.

  2012cites this paper
• The Current Status of Alzheimer's Disease Treatment

  2012cites this paper
• NF-κB-regulated, proinflammatory miRNAs in Alzheimer's disease

  2012cites this paper
• Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease.

  2012cites this paper
• Assessment of Inflammation as an Alzheimer's Disease Predictor

  2012cites this paper
• Alzheimer's Disease: Advances in Theory and Treatment

  2012cites this paper
• Current and Emerging Drug Treatment Options for Alzheimer’s Disease

  2011cites this paper
• Immune suppression and immune activation in depression.

  2011cites this paper
• Modeling neurodegenerative disease pathophysiology in thiamine deficiency: consequences of impaired oxidative metabolism.

  2011cites this paper
• A Versatile High Throughput Screening System for the Simultaneous Identification of Anti-Inflammatory and Neuroprotective Compounds

  2010cites this paper
• Inflammation-associated risk factors for Alzheimer s disease and dementia

  2010cites this paper
• An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease

  2009cites this paper
• Chronic brain inflammation impairs two forms of long-term potentiation in the rat hippocampal CA1 area.

  2009cites this paper
• Association of C‐reactive protein with mild cognitive impairment

  2009cites this paper
• Alzheimer’s Disease and Mild Cognitive Impairment

  2009cites this paper
• Effect of excessive cholesterol and lipopolysaccharide on cerebellar neuronal cells in in vitro and protective role of anti-inflammatory drugs.

  2009cites this paper
• The blood brain barrier and the role of cytokines in neuropsychiatry.

  2009cites this paper
• Impairment of long-term depression induced by chronic brain inflammation in rats.

  2009cites this paper
• Dramatic Shifts in Circulating CD4 but not CD8 T Cell Subsets in Mild Alzheimer's Disease

  2009cites this paper
• Decline of Immune Responsiveness: A Pathogenetic Factor in Alzheimer's Disease?

  2009cites this paper
• Imaging microglial activation in Alzheimer's disease: what does it mean?

  2008cites this paper
• Lack of association between TNF-alpha polymorphisms and Alzheimer's disease in an Italian cohort.

  2008cites this paper
• Pharmacodynamics of Memantine: An Update

  2008cites this paper
• Amyloid β‐peptide activates nuclear factor‐κB through an N‐methyl‐D‐aspartate signaling pathway in cultured cerebellar cells

  2008cites this paper
• Amyloid beta-peptide activates nuclear factor-kappaB through an N-methyl-D-aspartate signaling pathway in cultured cerebellar cells.

  2008cites this paper
• maging Microglial Activation in Alzheimer ’ s Disease : hat Does It Mean ?

  2008cites this paper
• Non-steroidal anti-inflammatory agents, tolmetin and sulindac attenuate quinolinic acid (QA)-induced oxidative stress in primary hippocampal neurons and reduce QA-induced spatial reference memory deficits in male Wistar rats.

  2007cites this paper
• Pharmacology of Inflammation

  2007cites this paper
• Aspirin and anti‐inflammatory drugs for Alzheimer's disease

  2007cites this paper
• Alzheimer's disease and mild cognitive impairment.

  2007cites this paper
• Management of mild to moderate Alzheimer's disease and dementia

  2007cites this paper
• Dementia: The Significance of Cerebral Metabolic Disturbances in Alzheimer's Disease. Relation to Parkinson's Disease

  2007cites this paper
• Non-steroidal anti-inflammatory agents, tolmetin and sulindac, attenuate oxidative stress in rat brain homogenate and reduce quinolinic acid-induced neurodegeneration in rat hippocampal neurons

  2006cites this paper
• Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

  2006cites this paper
• Increased hippocampal nitric oxide synthase activity and stress responsiveness after imipramine discontinuation: Role of 5HT2A/C-receptors

  2006cites this paper